Project Grant HT94252410525
Award Date
5/15/24
Completion Date
5/14/27
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Bloomington, IN 47405, USA
Similar Awards
This $1,323,505 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to explore immune-tumor cell metabolic interactions in prostate cancer among African American men. The grant recipient, Trustees of Indiana University, will leverage its expertise in biomedical sciences and public health to conduct this innovative research initiative. The award has a performance period from August 1, 2024 to July 31, 2027....
This federal Project Grant award of $2,028,000.00, awarded on April 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at identifying epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The award was granted to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution in New York City. Through this...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Kentucky Research Foundation focused on "Targeting MNK/GRP78 Pathway to Disrupt Proteostasis Rewiring in Castration-Resistant Prostate Cancer". The $1,602,137 award, spanning from April 2025 to April 2028, aims to investigate innovative medical solutions for military personnel and the broader...
The Defense Health Agency awarded a $1,561,500 Project Grant to Health Research, Inc. Roswell Park Division for the period of March 15, 2023 through March 14, 2026. The grant will support research into slow-cycling prostate cancer cells in therapy resistance, disease relapse, and metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions for...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This federal Project Grant award of $564,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by The Institute For Cancer Research (ICR) to explore the role of the MUL1 gene in prostate cancer development. The award period runs from May 1, 2025 to April 30, 2027. ICR, a non-profit research organization, will perform this advanced biomedical research to help transform healthcare for military service...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...